

**Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials**

Hill AM, Mitchell N, Hughes S, Pozniak AL.

Current opinion in HIV and AIDS

2018; 13(2):102-111

**ARTICLE IDENTIFIERS**

DOI: 10.1097/COH.0000000000000445

PMID: 29278532

PMCID: not available

**JOURNAL IDENTIFIERS**

LCCN: 2006214351

pISSN: 1746-630X

eISSN: 1746-6318

OCLC ID: 70204200

CONS ID: not available

US National Library of Medicine ID: 101264945

This article was identified from a query of the SafetyLit database.